IRIS
ZAJA, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.285
EU - Europa 2.834
AS - Asia 702
Continente sconosciuto - Info sul continente non disponibili 14
AF - Africa 4
SA - Sud America 4
OC - Oceania 2
Totale 15.845
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.236
UA - Ucraina 1.168
DE - Germania 442
CN - Cina 432
FI - Finlandia 340
IT - Italia 338
SE - Svezia 246
IE - Irlanda 185
TR - Turchia 111
SG - Singapore 79
CA - Canada 45
GB - Regno Unito 45
IR - Iran 27
VN - Vietnam 25
RU - Federazione Russa 22
BE - Belgio 18
IN - India 17
EU - Europa 14
FR - Francia 9
CH - Svizzera 7
KR - Corea 5
CZ - Repubblica Ceca 4
BR - Brasile 3
MX - Messico 3
AU - Australia 2
HK - Hong Kong 2
MA - Marocco 2
NL - Olanda 2
RO - Romania 2
RS - Serbia 2
AN - Antille olandesi 1
EG - Egitto 1
ES - Italia 1
GR - Grecia 1
IL - Israele 1
JP - Giappone 1
LU - Lussemburgo 1
LV - Lettonia 1
PE - Perù 1
SA - Arabia Saudita 1
TG - Togo 1
TW - Taiwan 1
Totale 15.845
Salva come PNG Salva come JPEG
Città #
Fairfield 1.819
Woodbridge 1.736
Houston 1.138
Ann Arbor 968
Jacksonville 768
Ashburn 730
Seattle 708
Wilmington 677
Cambridge 616
Chandler 543
Dearborn 503
Boardman 234
Beijing 197
Princeton 197
Dublin 185
Udine 130
Izmir 111
San Diego 94
Singapore 52
Ogden 47
Des Moines 42
Nanjing 36
Norwalk 36
Ottawa 34
Kunming 28
Dong Ket 25
Florence 25
New York 24
Hefei 23
Brussels 18
Andover 17
Saint Petersburg 16
Dallas 15
Guangzhou 14
Jinan 14
Shenyang 14
Falls Church 12
Leawood 12
Nanchang 11
San Mateo 11
Lappeenranta 10
Trieste 10
Ardabil 9
Helsinki 9
Grafing 8
Simi Valley 8
Toronto 8
Chengdu 7
Fremont 7
Los Angeles 7
Venezia 7
Fuzhou 6
Indiana 6
Zanjan 6
Codroipo 5
Hebei 5
Munich 5
Wuhan 5
Zhengzhou 5
Zurich 5
Augusta 4
Bari 4
Chongqing 4
Milan 4
Monmouth Junction 4
Nanning 4
Ningbo 4
Washington 4
Arcadia 3
Castelnuovo Rangone 3
Changsha 3
Giessen 3
Henderson 3
Maserada Sul Piave 3
Padova 3
Palmanova 3
Sacramento 3
San Francisco 3
Santa Clara 3
Aguascalientes 2
Belgrade 2
Casablanca 2
Chaoyang 2
Clifton 2
Edinburgh 2
Fayetteville 2
Foggia 2
Hong Kong 2
Jiaxing 2
Kashan 2
Kish 2
Langfang 2
Las Vegas 2
Mumbai 2
Olomouc 2
Redwood City 2
Saluzzo 2
San Francesco 2
Scafati 2
São Paulo 2
Totale 12.125
Salva come PNG Salva come JPEG
Nome #
The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery 144
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial 139
Low-dose rituximab in adult patients with primary immune thrombocytopenia. 136
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia 134
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma 132
Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries 132
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 132
Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection 131
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers 130
Activity of all-trans-retinoic acid in a case of central nervous system extramedullary relapse of acute promyelocytic leukemia 128
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. 127
Earlier administration of Rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia 125
Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 124
Impact of clinical data on chest radiography sensitivity in detecting pulmonary abnormalities in immunocompromised patients with suspected pneumonia 124
Management of immune thrombocytopenia in elderly patients 123
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 122
Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma. 120
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results 120
More on false thrombocytopenias: EDTA-dependent pseudothrombocytopenia associated with a congenital platelet release defect. 118
Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT 118
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 118
Clonality and phenotype in spleens from patients with primary immune thrombocytopenia. 118
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. 117
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 117
Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas. 117
Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice. 116
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. 115
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 114
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials 114
Efficacy and safety of rituximab in type II mixed cryoglobulinemia 113
Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia 112
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study 111
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 110
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial 109
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: A retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO 109
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 106
Peripheral T-cell lymphoma unspecified PTCL-U): a new prognostic model from a retrospective multicentric clinical study 105
Rituximab for the treatment of type II mixed cryoglobulinemia 104
CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma 104
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 104
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 104
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations 103
Incidence and diagnosis of EDTA-dependent pseudothrombocytopenia in a consecutive outpatient population referred for isolated thrombocytopenia. 102
Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination 102
NOTCH1 mutational status in chronic lymphocytic leukaemia: Clinical relevance of subclonal mutations and mutation types 102
Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. 101
Two cases of concomitant diffuse large B-cell lymphoma and myelodysplastic syndrome. 100
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. 100
Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. 99
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. 99
Surgical staging in Hodgkin's disease: the role of laparoscopic splenectomy 99
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma. Phase II study of 32 patients 99
Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia 99
Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. 98
Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. 98
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. 98
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia 98
Impact of hepatitis C virus infection on clinical features, quality of life and survival of patients with lymphoplasmacytoid lymphoma/immunocytoma 97
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients 97
BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine 97
Delayed and long-lasting complete response to fludarabine in two patients with B-cell chronic lymphocytic leukemia. 96
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma 96
The role of Rituximab in the therapy of mixed cryoglobulinemia 96
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 96
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 96
Rituximab-responsive CIDP. 96
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation 95
New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? 95
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia 95
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 94
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 94
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. 94
Efficacy of selective B cell Blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells 93
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. 92
Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma. 92
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. 92
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network. 92
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells 91
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: A proposal for clinical application 91
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 90
Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. 89
Acute hepatic failure as onset of progressive sclerodermatous chronic graft-versus-host disease after donor lymphocyte infusion. 89
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 88
153) LAPAROSCOPIC SPLENECTOMY FOR MASSIVELY ENLARGED SPLEENS: TECHNICAL ASPECTS AND RESULTS OF 8 CONSECUTIVE CASES 87
The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. 87
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi 87
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma 87
HSV-1 cutaneous infection in a patient with Hodgkin's lymphoma treated with brentuximab vedotin. 86
Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. 86
Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous transplantation 85
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation 85
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. 85
Persistent CD49d engagement in circulating CLL cells: A role for blood-borne ligands? 85
Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia 84
Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia 84
FEASIBILITY AND OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OLDER THAN 60 YEARS WITH POOR RISK ACUTE MYELOID LEUKEMIA 83
Treatment of refractory chronic GVHD with rituximab: a GITMO study 83
Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. 83
Bendamustine salvage therapy for T cell neoplasms. 83
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. 83
Totale 10.369
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.789
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.789
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.483 0 0 205 796 371 802 580 564 385 367 88 325
2020/20212.666 38 344 83 350 73 357 187 328 315 119 300 172
2021/20221.580 57 183 71 109 52 78 100 87 15 261 303 264
2022/20231.323 214 72 20 135 141 398 0 91 171 18 34 29
2023/2024381 60 22 10 14 69 46 22 14 65 25 15 19
2024/2025304 52 252 0 0 0 0 0 0 0 0 0 0
Totale 16.297